Medical Treatments for Prostate CancerThere are many different medical treatments for prostate cancer that involve the clinical care of a healthcare professional. These treatments include expectant therapy, surgery, radiation therapy, hormone therapy, and chemotherapy. Expectant therapy is to carefully observe and monitor the prostate cancer. Because prostate cancer cells often spread very slowly, many older men who have the disease may not need more extensive treatment. However, expectant therapy usually includes routine physician examinations, including digital rectal exams and PSA tests. The different types of surgery for prostate cancer are radical prostatectomy - an open-surgery procedure in which the entire prostate gland and surrounding tissue are removed. Transurethral resection of the prostate (TURP) - surgery to remove part of the prostate gland that surrounds the urethra. Cryosurgery - this procedure involves killing the cancer cells by freezing them with a small metal tool placed in the tumor. Side effects of prostate cancer surgery include incontinence and impotence. Incontinence is the inability to control urine and may result in dribbling of urine, especially immediately after surgery. Normal control usually returns within weeks or months after surgery. Impotence is the inability to achieve an erection. For a month, or so, after surgery, most men are not able to get an erection. Eventually, approximately 40 to 60 percent of men will be able to get an erection sufficient for sexual intercourse, but without ejaculation of semen, since removal of the prostate gland prevents that process.Radiation therapy uses high energy rays to kill or shrink cancer cells, and to decrease their ability to divide. Radiation is often used to treat prostate cancer that is still confined to the prostate gland, or has spread only to nearby tissue. If the disease is advanced, radiation may be used to reduce the size of the tumor and to provide relief from symptoms. Possible side effects of radiation for prostate cancer may include diarrhea, with or without blood in the stool, and colitis, problems associated with urination, a degree of impotence (inability to get an erection), which may occur within two years of radiation therapy. The goal of hormone therapy is to lower the level of male hormones in the body, particularly testosterone. Hormone therapy does not cure the cancer, and is often used to treat persons whose cancer has spread or recurred after treatment. Produced mainly in the testicles, testosterone causes prostate cancer cells to grow. Thus, reduced testosterone levels can make the prostate cancer shrink and become less active. Most studies show that hormone therapy works better if it is started early. Chemotherapy is the use of powerful, anti-cancer medications to kill cancer cells.. Hospitalization may be needed to monitor treatment and chemotherapy's side effects. Common side effects of chemotherapy include: nausea and vomiting, hair loss, anemia, reduced ability of blood to clot, mouth sores, increased likelihood of developing infections, fatigue. Most side effects disappear once treatment is stopped. |
| hormone refractory prostate cancer incidence |
|
Which drug combination for hormone-refractory prostate cancer? antrone/prednisone in hormone-refractory prostate cancer and both should . There was a higher incidence of impaired left ventricular In Vivo Suppression of Hormone-Refractory Prostate Cancer Growth Here, we used s.c. hormone-refractory human DU145 prostate tumor xenograft .. in the reduced risk and incidence of colorectal cancer (29) ; however, Zoledronic Acid in Hormone-Refractory Metastatic Prostate Cancer To validate the therapeutic effects of zoledronic acid, we conducted a study in which patients with hormone-refractory prostate cancer and a history of bone Role of Chemotherapy in Hormone-Refractory Prostate Cancer prostate cancer incidence rose rapidly, a likely result of patients with hormone refractory prostate. carcinoma. Cancer 2001;91:2039â“2045. Taxotere (docetaxel) significantly improves the survival of in patients with metastatic hormone refractory prostate cancer - Prostate cancer ranks third worldwide in cancer incidence and sixth in cancer mortality StreetInsider.com - Prostate Cancer - Hormone-Refractory Patients Epidemiology of prostate cancer 46 Incidence of prostate cancer 46 . Drug therapy for hormone-refractory prostate cancer 140 Use of drug therapy for HRPC UMCCC Publications - Michigan Oncology Journal Spring 98 Recent Changes in Michiganâ™s Prostate Cancer Incidence: What Does It Mean? New Therapy for Hormone Refractory Prostate Cancer Management of hormone refractory prostate cancer poses a Studies reviewing tomato lycopene and the incidence of prostate cancer risk Some studies have found a lower incidence of prostate cancer in populations PSA flare-up in patients with hormone-refractory prostate cancer PSA flare-up in patients with hormone-refractory prostate cancer (HRPCA) receiving docetaxel-based chemotherapy: Incidence and differentiation from Anemia in Men with Advanced Prostate Cancer: Incidence, Etiology This article reviews the incidence and examines the various causes of this . for hormone-refractory prostate cancer: a Southwest Oncology Group report. A retrospective analysis of cardiovascular morbidity in metastatic decreased the incidence of prostate cancer, further suggesting the benefits of COX-2 hormone-refractory prostate cancer (mHRPC) who were The role of bisphosphonates in hormone-refractory prostate cancer The incidence of skeletal. morbidity is illustrated by the placebo group of a study. of zoledronic acid in men with hormone-refractory. prostate cancer Clinical Oncology : Management of patients with hormone refractory The management of hormone refractory prostate cancer (HRPC) is 1 A. Majeed, P. Babb, J. Jones and M. Quinn, Trends in prostate cancer incidence, Metastatic And Hormone Refractory Prostate cancer Metastatic And Hormone Refractory Prostate cancer (HRPC) Etiology 28; Epidemiology 30; Incidence forecasts 32; Point prevelence forecasts 33 Prostate cancer - Wikipedia, the free encyclopedia "International trends and patterns of prostate cancer incidence and mortality". of androgen receptor gene in hormone-refractory prostate cancer. Chemotherapy for hormone-refractory prostate cancer Prostate cancer mainly affects elderly men, and its incidence has steadily in men with hormone-refractory prostate cancer (HRPC) for many years, Stakeholder Insight: Metastatic And Hormone Refractory Prostate cancer Stakeholder Insight: Metastatic And Hormone Refractory Prostate cancer | Strategic Table 2: Forecast incidence of prostate cancer in the seven major |
| hormone refractory prostate cancer incidence |
|
massage prostate services prostate cancer gleason 7 milking the prostate gland lupron injection for prostate cancer |